Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Drugs used off label to treat raised ICP also have cognitive side effects, underscoring the unmet need for effective therapeutics which reduce ICP without worsening cognition
FDA has approved Lipfendra (enlicitide), making it the world's first oral PCSK9 inhibitor for lowering LDL ("bad") cholesterol
The slowing effect is strongest early in treatment and right after a dose increase, and it tends to ease as the body adapts to a steady dose
Xie J, Yang M, Xing Y
Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds
US$ 21.81
US$ 20.67
US$ 27.33
